Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ)

1. Executive Overview: Defining BRONJ

Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ), clinically categorized under ICD-10 code M27.8, represents a severe and debilitating adverse drug reaction characterized by the progressive destruction of bone tissue in the mandible or maxilla. In contemporary clinical literature, this condition is increasingly referred to as Medication-Related Osteonecrosis of the Jaw (MRONJ) to encompass a broader range of antiresorptive and antiangiogenic agents beyond bisphosphonates.

The condition is defined by the presence of exposed, necrotic bone in the maxillofacial region that persists for more than eight weeks in patients who have received antiresorptive or antiangiogenic therapy, provided there is no history of radiation therapy to the jaws or metastatic disease to the jaws. As a specialist in oral and maxillofacial surgery, it is imperative to recognize that while bisphosphonates are vital for managing osteoporosis and bone metastases, their potent inhibition of osteoclasts creates a unique environment in the jaw that inhibits physiological bone remodeling, leading to necrosis.

2. Pathophysiology, Etiology, and Risk Factors

The Mechanism of Action

Bisphosphonates are synthetic analogs of inorganic pyrophosphate. They possess a high affinity for hydroxyapatite crystals, allowing them to bind to bone surfaces. When osteoclasts attempt to resorb this bone, they ingest the bisphosphonates, which disrupts the mevalonate pathway, triggers osteoclast apoptosis, and effectively halts bone turnover.

Why the Jaw?

The jaw is uniquely susceptible to necrosis compared to other skeletal sites for three primary reasons:
1. High Turnover Rate: The alveolar bone has a significantly higher rate of remodeling than long bones, making it more dependent on the osteoclast-osteoblast coupling mechanism.
2. Micro-trauma: The jaw is subjected to constant masticatory stress and micro-trauma from dental occlusion.
3. Anatomical Vulnerability: The thin mucosal covering over the alveolar bone is easily breached by dental procedures, periodontal disease, or ill-fitting dentures, exposing the underlying bone to the complex oral microbiome.

Risk Factors

The risk of developing BRONJ is multifactorial and can be categorized into systemic and local factors:

3. Signs, Symptoms, and Clinical Presentation

The clinical presentation of BRONJ ranges from asymptomatic bone exposure to severe, debilitating pain and pathological fractures. Clinicians should be vigilant for the following signs:

• Exposed Bone: The hallmark sign is the presence of yellow or greyish necrotic bone that does not heal over an 8-week period.
• Soft Tissue Pathology: Recurrent soft tissue swelling, persistent purulent discharge, or non-healing extraction sockets.
• Sensory Changes: Patients may report numbness, tingling, or anesthesia in the distribution of the inferior alveolar nerve (often referred to as the "numb chin syndrome").
• Pain: While early stages may be asymptomatic, secondary infection often leads to intense, refractory pain.
• Secondary Infection: The exposed bone serves as a nidus for bacterial colonization, leading to fistula formation and localized lymphadenopathy.

4. Standard Diagnostic Evaluation & Workup

The diagnosis of BRONJ remains primarily clinical, supported by radiographic imaging.

Clinical Staging (AAOMS Criteria)

• Stage 0: No clinical evidence of necrotic bone, but nonspecific clinical findings or symptoms.
• Stage 1: Exposed/necrotic bone in asymptomatic patients without evidence of infection.
• Stage 2: Exposed/necrotic bone with evidence of infection (pain, erythema, purulence).
• Stage 3: Exposed/necrotic bone extending beyond the alveolar bone, resulting in pathological fracture, extra-oral fistula, or osteolysis.

Imaging Modalities

• Panoramic Radiography: Initial screening tool to identify sclerotic changes, persistent extraction sockets, or sequestra.
• Cone Beam Computed Tomography (CBCT): The gold standard for assessing the extent of osteonecrosis, identifying sequestra, and evaluating the integrity of the mandibular canal.
• MRI: Useful for identifying soft tissue involvement or marrow edema before clinical bone exposure becomes visible.

Laboratory Assays

While there is no specific blood test to diagnose BRONJ, clinicians may assess C-terminal telopeptide (CTX) levels. While controversial, some studies suggest that low levels of CTX (<100 pg/mL) may indicate a suppressed bone turnover rate, potentially increasing the risk of BRONJ following invasive procedures.

5. Therapeutic Interventions

Management is dictated by the stage of the disease and the patient’s underlying systemic health.

Non-Surgical Management (Staging 0-1)

• Conservative Debridement: Removal of sharp bony edges to eliminate soft tissue irritation.
• Antimicrobial Rinses: Chlorhexidine gluconate 0.12% to manage oral bioburden.
• Antibiotic Therapy: Systemic antibiotics (e.g., Penicillin V, Clindamycin, or Doxycycline) are indicated only during acute exacerbations of infection.

Surgical Management (Staging 2-3)

• Sequestrectomy: Surgical removal of necrotic bone fragments.
• Resection: In Stage 3 cases with extensive necrosis or pathological fractures, segmental resection of the jaw may be required, followed by reconstructive surgery.
• Soft Tissue Closure: Primary closure of the site is essential to prevent re-exposure.

The "Drug Holiday"

The decision to discontinue bisphosphonate therapy (the "drug holiday") must be made in close coordination with the patient's oncologist or primary care physician. Given the long half-life of these medications, stopping the drug may not immediately reduce the risk of BRONJ but is generally recommended before elective dentoalveolar surgery.

6. Frequently Asked Questions (FAQ)

1. Can BRONJ be cured?
While BRONJ is a chronic condition, it can be managed effectively. The primary goal is to eliminate pain, control infection, and prevent the progression of bone necrosis.

2. Is there a difference between BRONJ and MRONJ?
Yes. MRONJ (Medication-Related Osteonecrosis of the Jaw) is the broader, modern term that includes other drugs like RANK ligand inhibitors (e.g., Denosumab) and antiangiogenic agents, whereas BRONJ specifically refers to bisphosphonates.

3. How long do I need to stop my medication before a dental extraction?
Current guidelines suggest a consultation with your prescribing physician. Often, a "drug holiday" of 2-3 months prior to surgery is discussed, but this depends on the patient's individual risk profile.

4. Are dental implants safe for patients on bisphosphonates?
Implants carry an increased risk of failure and BRONJ in patients on long-term antiresorptive therapy. A thorough risk-benefit analysis is required.

5. How can I prevent BRONJ?
Maintain excellent oral hygiene, attend regular dental check-ups, and inform your dentist about any bone-strengthening medications you are taking.

6. Does the route of administration matter?
Yes. IV bisphosphonates (used for cancer) carry a significantly higher risk of BRONJ compared to oral bisphosphonates (used for osteoporosis).

7. Can BRONJ occur spontaneously?
Yes, though it is more common following dental trauma, it can occur spontaneously, especially in patients with poor oral hygiene or chronic periodontal disease.

8. Is pain a constant symptom?
Not always. Many patients with Stage 1 BRONJ are asymptomatic. Pain usually develops once secondary infection sets in.

9. What is a "sequestrum"?
A sequestrum is a piece of dead bone that has become separated from the healthy, living bone. It often requires surgical removal to allow the surrounding soft tissue to heal.

10. Do I need to stop taking my osteoporosis medication forever?
No. Most patients can eventually resume their therapy once the oral condition is stable, or they may be transitioned to a different class of medication, depending on their oncology or endocrinology status.

Disclaimer: This guide is for educational purposes only and does not replace professional medical advice. If you suspect you have symptoms of BRONJ, consult an oral and maxillofacial surgeon immediately.

Related Clinical Integration

The clinical management of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ)—now more broadly categorized as MRONJ—requires a multidisciplinary approach that integrates systemic pharmacological support with targeted surgical intervention. Patients presenting with necrotic bone lesions often necessitate a regimen of Antibiotics / المضادات الحيوية Standard to control secondary infection, alongside the frequent use of Antiseptic Solution (e.g., Chlorhexidine gluconate 2% or Povidone-iodine) / محلول مطهر (مثل غلوكونات الكلورهيكسيدين 2% أو بوفيدون-يود) Standard for local oral hygiene. When conservative measures fail, surgical Debridement of Osteomyelitis (Sequestrectomy) (عملية كبرى في غرف العمليات) becomes essential to remove devitalized tissue, utilizing specialized tools such as the Bone Rongeur (Leksell) / ملقط عظم (ليكسيل) or, in specific soft-tissue debridement contexts, the Sims Uterine Curette / مكشطة رحم سيمز. While procedures like Ankle Arthroscopy (Diagnostic/Debridement) / تنظير مفصل الكاحل (تشخيصي/تنضير) (عملية كبرى في غرف العمليات) are unrelated to the jaw, the broader principles of bone viability and surgical debridement are thoroughly explored in our educational resources on Osteonecrosis (AVN): Pathophysiology, Epidemiology & Clinical Manifestations and the [Orthopedic Management of Bisphosphonate Complications: MRONJ & Atypical Femoral Fractures](https://www.hutaifortho.com/en/hub/pathologic-fractures/orthopedic-oncology-cases-side